<DOC>
	<DOCNO>NCT01528085</DOCNO>
	<brief_summary>The goal trial evaluate efficacy tolerance combination nilotinib chemotherapy front-line set induction consolidation therapy Ph+ ALL patient age 55 year . A European consensus reach adopt common chemotherapeutic schedule patient age 55 year . This schedule use trial addition nilotinib concomitant therapy induction , consolidation maintenance . The patient prospectively monitor minimal residual disease bcr-abl tyrosine kinase domain mutation .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Nilotinib Combination With Chemotherapy Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<criteria>1 . Male female patient &gt; 55 year 2 . Philadelphia chromosome BCRABL positive acute lymphoblastic leukemia 3 . Not previously treat except corticosteroid single dose vincristine ( three dos cyclophosphamide accept ) 4 . With without documented CNS involvement 5. WHO performance status &lt; 2 6 . Normal serum level &gt; LLN ( low limit normal ) potassium , magnesium , total calcium correct serum albumin ; correct within normal limit supplement , prior first dose study medication 7 . Signed write inform consent 8 . Molecular evaluation BCRABL perform 9 . Willingness male subject whose sexual partner woman childbearing potential ( WOCBP ) , use effective form contraception ( pearl index &lt; 1 % ) , complete sexual abstinence , combine oral contraceptive , hormone IUCD , vaginal hormone ring , transdermal contraceptive patch , contraceptive implant depot contraceptive injection combination second method contraception like condom cervical cap / diaphragm spermicide surgical sterilisation ( vasectomy ) male patient study least 6 month thereafter . WOCBP define sexually mature woman undergone hysterectomy surgical sterilization naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . 1 . Patient previously treat tyrosine kinase inhibitor 2 . Known impaired cardiac function , include follow : LVEF &lt; 45 % Complete leave bundle branch block Right bundle branch block plus leave anterior hemiblock , bifascicular block Use ventricularpaced pacemaker Congenital long QT syndrome History presence clinically significant ventricular atrial tachyarrhythmias Clinically significant rest bradycardia ( &lt; 50 beat per minute ) QTcF &gt; 450 msec screen ECG . If QTc &gt; 450 msec electrolyte within normal range nilotinib dose , electrolyte correct patient rescreened QTcF criterion . Myocardial infarction 12 month prior start nilotinib Other clinical significant heart disease ( e.g . unstable angina , congestive heart failure , uncontrolled hypertension ) 3 . Patients history another primary malignancy currently clinically significant currently require active intervention 4 . Known diagnosis human immunodeficiency virus ( HIV ) infection ( HIV test mandatory ) know infection Hepatitis B C 5 . Treatment , investigational agent participate another trial within 30 day prior enter study 6 . Inadequate hepatic function define ASAT ALAT &gt; 2,5 time institutional upper limit normal &gt; 5 time ULN consider due leukemia 7 . Total bilirubin &gt; 2 fold institutional upper limit unless consider due organ involvement leukemia M. Gilbert / M. Meulengracht 8 . Concurrent severe disease exclude administration therapy 9 . Past history acute chronic pancreatits 10 . Patients unwilling unable comply protocol.e branch block ; Right bundle branch block plus leave anterior hemiblock , bifascicular block ; Use ventricularpaced pacemaker ; congenital long QT syndrome History presence clinically significant ventricular atrial tachyarrhythmias Clinically significant rest bradycardia ( &lt; 50 beat per minute ) QTcF &gt; 450 msec screen ECG . If QTc &gt; 450 msec electrolyte within normal range nilotinib dose , electrolyte correct patient rescreened QTcF criterion . Myocardial infarction 12 month prior start nilotinib Other clinical significant heart disease ( e.g . unstable angina , congestive heart failure , uncontrolled hypertension ) Patients history another primary malignancy currently clinically significant currently require active intervention Known diagnosis human immunodeficiency virus ( HIV ) infection ( HIV test mandatory ) know infection Hepatitis B C Treatment , investigational agent participate another trial within 30 day prior enter study Inadequate hepatic function define ASAT ALAT &gt; 2,5 time institutional upper limit normal &gt; 5 time ULN consider due leukemia Total bilirubin &gt; 2 fold institutional upper limit unless consider due organ involvement leukemia M. Gilbert / M. Meulengracht Concurrent severe disease exclude administration therapy Past history acute chronic pancreatits Patients unwilling unable comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Philadelphia chromsome</keyword>
	<keyword>BCR-ABL</keyword>
	<keyword>ALL</keyword>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>Nilotinib</keyword>
	<keyword>Tasigna</keyword>
</DOC>